Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT03924856
- 3475-866, 2018-003808-39, MK-3475-866, 194870
Trial sponsor
Merck
Scientific Title
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer